Evidence map›Paper›PMID 26443048›Full record

ArticleJournal of neurochemistry2016

Simvastatin inhibits neural cell apoptosis and promotes locomotor recovery via activation of Wnt/β-catenin signaling pathway after spinal cord injury.

Kai Gao, Zhaoliang Shen, Yajiang Yuan, Donghe Han, Changwei Song, Yue Guo, Xifan Mei

Open access · hybridAbstract read
In one paragraph

Article in Journal of neurochemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 97 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Wnt/β-catenin Signaling in Central Nervous System Regeneration.Advances in experimental medicine and biology · 2025
    Review
  7. Article
  8. Review
  9. Article
  10. The roles of circular RNAs in nerve injury and repair.Frontiers in molecular neuroscience · 2024
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Kai GaoDepartment of Orthopedics, First Affiliated Hospital of Liaoning Medical University, Jinzhou, China.
Zhaoliang ShenDepartment of Orthopedics, Second Hospital of Jinzhou, Jinzhou, China.
Yajiang YuanDepartment of Orthopedics, First Affiliated Hospital of Liaoning Medical University, Jinzhou, China.
Donghe HanDepartment of Neurobiology and Key Laboratory of Neurodegenerative Diseases of Liaoning Province, Liaoning Medical University, Jinzhou, China.
Changwei SongDepartment of Orthopedics, First Affiliated Hospital of Liaoning Medical University, Jinzhou, China.
Yue GuoDepartment of Orthopedics, First Affiliated Hospital of Liaoning Medical University, Jinzhou, China.
Xifan MeiDepartment of Orthopedics, First Affiliated Hospital of Liaoning Medical University, Jinzhou, China.
First Affiliated Hospital of Liaoning Medical University · CNJinzhou Central Hospital · CNJinzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Statins exhibit neuroprotective effects after spinal cord injury (SCI). However, the molecular mechanism underlying these effects remains unknown. This study demonstrates that the hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin (Simv) exhibits neuroprotective effects on neuronal apoptosis and supports functional recovery in a rat SCI model by activating the Wnt/β-catenin signaling pathway. In specific, Simv administration after SCI significantly up-regulated the expression of low density lipoprotein receptor-related protein 6 phosphorylation and β-catenin protein, increased the mRNA expression of lymphoid enhancer factor-1 and T-cell factor-1, and suppressed the expression of β-catenin phosphorylation in the spinal cord neurons. Simv enhanced motor neuronal survival in the spinal cord anterior horn and decreased the lesion of spinal cord tissues after SCI. Simv administration after SCI also evidently reduced the expression levels of Bax, active caspase-3, and active caspase-9 in the spinal cord neurons and the proportion of transferase UTP nick end labeling (TUNEL)-positive neuron cells, but increased the expression level of Bcl-2 in the spinal cord neurons. However, the anti-apoptotic effects of Simv were reduced in cultured spinal cord nerve cells when the Wnt/β-catenin signaling pathway was suppressed in the lipopolysaccharide-induced model. Furthermore, the Basso, Beattie, and Bresnahan scores indicated that Simv treatment significantly improved the locomotor functions of rats after SCI. This study is the first to report that Simv exerts neuroprotective effects by reducing neuronal apoptosis, and promoting functional and pathological recovery after SCI by activating the Wnt/β-catenin signaling pathway. We verified the neuroprotective properties associated with simvastatin following spinal cord injury (SCI). Simvastatin reduced neuronal apoptosis, improved the functional and pathological recovery via activating Wnt/β-catenin signal pathway, however, the anti-apoptosis effects of simvastatin were reversed following suppressing Wnt/β-catenin signaling pathway in primary spinal cord neurons. The significant findings may provide clinical therapeutic value of simvastatin for treating SCI.

Indexed as

AnimalsApoptosisbeta CateninCells, CulturedDisease Models, AnimalEmbryo, MammalianGene Expression RegulationHydroxymethylglutaryl-CoA Reductase InhibitorsLipopolysaccharidesLocomotionMaleMovement DisordersNeuronsRatsRats, Sprague-DawleyRecovery of Functionbeta CateninHydroxymethylglutaryl-CoA Reductase InhibitorsLipopolysaccharidesSimvastatinWnt Proteinsapoptosisneuroprotectionsimvastatinspinal cord injuryWnt/β-catenin

Identifiers

PMID26443048
PMCPMC5089634
OpenAlexW1827374308

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.